Mineralys CEO Sells Shares Ahead of December FDA Date
Mineralys Therapeutics' CEO, Jon Congleton, sold 10,700 shares on July 13, 2026. The sale was conducted under a Rule 10b5-1 trading plan and represents a modest adjustment to his holdings. With the company's stock up 90% over the past year and an upcoming FDA decision in December, this insider activity may influence investor sentiment.
Tickers: $MLYS